Copyright
©The Author(s) 2021.
World J Gastroenterol. May 21, 2021; 27(19): 2312-2324
Published online May 21, 2021. doi: 10.3748/wjg.v27.i19.2312
Published online May 21, 2021. doi: 10.3748/wjg.v27.i19.2312
Table 1 The risk of hepatitis B virus reactivation in patients treated with interleukin-12/23 or interleukin-23 inhibitors
Ref. | Number of HBV patients | HBV status | Disease | Drugs | Prophylaxis | Follow-up | HBV reactivation |
Ting et al[27], 2018 | 54 | (1) 10 CHB; and (2) 44 resolved HBV. HBV-DNA at baseline (-) | Psoriasis | Ustekinumab | Yes: 2 patients with CHB | 24 mo | (1) 2 patients with CHB without prophylaxis. (no hepatitis); and (2) 1 patient with resolved HBV (mild hepatitis) |
Solay et al[5], 2018 | 29 | 29 resolved HBV. HBV-DNA at baseline (-) | Psoriasis/HS/AS/RA/CD | Ustekinumab (n = 7) | NA | 22 wk | 1 patient with psoriasis without prophylaxis (no data regarding hepatitis) |
Sanz-Bueno et al[68], 2015 | 20 | 20 resolved HBV. HBV-DNA at baseline (-) but viral load was assessed in 7 of 20 patients | Psoriasis | Ustekinumab (n = 6) | No | 40 mo | 0 |
Chiu et al[28], 2013 | 14 | (1) 11 CHB; and (2) 3 resolved HBV. HBV-DNA at baseline was not available | Psoriasis | Ustekinumab | Yes: 4 patients with CHB | 10 mo | (1) 2 patients with CHB without prophylaxis (No hepatitis); and (2) 0 |
Navarro et al[69], 2013 | 5 | 5 CHB | Psoriasis | Ustekinumab (n = 1) | Yes | 25 mo | 0 |
Hayashi et al[70], 2014 | 5 | 5 resolved HBV. HBV-DNA at baseline was not available | Psoriasis | Ustekinumab | No | 52 wk | 0 |
Koskinas et al[41], 2013 | 1 | Resolved HBV. HBV-DNA at baseline was not available | Psoriasis | Ustekinumab | No | 16 mo | 1 with hepatitis (ALT 65 IU/mL) |
Steglich et al[71], 2014 | 1 | Resolved HBV. HBV-DNA at baseline (-) | Psoriasis | Ustekinumab | Yes | 36 mo | 0 |
Duncan et al[43], 2019 | 1 | Resolved HBV. HBV-DNA at baseline was not available | Palmoplantar Psoriasis | Guselkumab | No | 12 mo | 0 |
- Citation: Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324
- URL: https://www.wjgnet.com/1007-9327/full/v27/i19/2312.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i19.2312